Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1542/peds.2004-0416 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Since treatment with anticoagulants can prevent recurrent strokes, identification of patients at risk for incident AF after stroke is crucial. We aimed to investigate whether the addition of AF polygenic risk scores (PRS) to existing clinical risk predictors could improve prediction of AF after stroke. Patients diagnosed with ischemic stroke at Massachusetts General Hospital between 2003-2017 were included.
View Article and Find Full Text PDFFive year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening.
PLoS One
January 2025
Respiratory Medicine, NHS Tayside, Dundee, United Kingdom.
The role of biomarkers in risk-based early detection of lung cancer may enable screening to become cost effective and widely accessible. EarlyCDT-Lung is an example of such a blood-based autoantibody biomarker which may improve accessibility to Low dose Computed Tomography (LDCT) screening for those at highest risk. We randomized 12 208 individuals aged 50-75 at high risk of developing lung cancer to either the test or to standard clinical care.
View Article and Find Full Text PDFPerceived Biological Bases of Sexual Orientation and Sexual Prejudice: The Moderating Role of Gender and Religious Beliefs.
Arch Sex Behav
December 2024
Faculty of Behavioural and Social Sciences, University of Groningen, Groningen, The Netherlands.
Prior correlational studies have shown that belief in the biological theory of sexual orientation (BTSO) is associated with more positive attitudes toward homosexuality. However, individuals often interpret scientific evidence in ways that align with their pre-existing beliefs and motivations. This research experimentally investigated whether gender and religiosity moderate heterosexual individuals' responses to scientific evidence either supporting or refuting BTSO.
View Article and Find Full Text PDFA phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.
Blood Adv
December 2024
City of Hope, Duarte, California, United States.
The anti-apoptotic protein myeloid cell leukemia-1 (Mcl-1) contributes to the pathophysiology of acute myeloid leukemia (AML) and certain B-cell malignancies. Tumor dependence on Mcl-1 is associated with resistance to venetoclax. Voruciclib, an oral cyclin-dependent kinase (CDK) inhibitor targeting CDK9, indirectly decreases Mcl-1 protein expression and synergizes with venetoclax in preclinical models.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!